ARMP Overview

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.

Wall Street analysts forecast ARMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARMP is12.00 USD with a low forecast of 9.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Armata Pharmaceuticals Inc revenue for the last quarter amounts to 789.00K USD, increased 60.69

Armata Pharmaceuticals Inc. EPS for the last quarter amounts to -3.16 USD, increased 1655.56

Armata Pharmaceuticals Inc (ARMP) has 61 emplpoyees as of May 17 2026.

Today ARMP has the market capitalization of 295.52M USD.